Glaxo gives up on cancer trial

Julian Harris
Follow Julian
UK-BASED pharmaceuticals giant GlaxoSmithKline announced yesterday that it has called time on clinical trials for a vaccine to tackle lung cancer.

Its shares closed down 0.7 per cent after the company said it is not possible to find a sub-group of patients that could benefit.

Glaxo warned on 20 March that the so-called Mage-A3 vaccine did not seem to be helping patients in the Phase III trials. “We hope that the data generated in this trial will advance our understanding of the science of immunotherapeutics and ultimately towards development of new therapies,” said senior vice-president Vincent Brichard.